Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126809842 | 12680984 | 2 | F | 20160531 | 20160824 | 20160824 | EXP | CN-BAYER-2016-159592 | BAYER | 50.00 | YR | A | F | Y | 0.00000 | 20160824 | MD | CN | CN |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126809842 | 12680984 | 1 | SS | ADALAT | NIFEDIPINE | 1 | Oral | 30 MG, QD | 0 | 30 | MG | PROLONGED-RELEASE TABLET | QD | ||||||
| 126809842 | 12680984 | 2 | PS | Bayaspirin | ASPIRIN | 1 | Oral | 100 MG, QD | 21317 | 100 | MG | COATED TABLET | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126809842 | 12680984 | 1 | Hypertension |
| 126809842 | 12680984 | 2 | Hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126809842 | 12680984 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126809842 | 12680984 | Blood pressure inadequately controlled | |
| 126809842 | 12680984 | Headache | |
| 126809842 | 12680984 | Off label use | |
| 126809842 | 12680984 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126809842 | 12680984 | 1 | 2014 | 0 |